04, 2025 (GLOBE NEWSWIRE) -- Noom, the leading digital healthcare company committed to chronic disease prevention and empowering people to live better longer, today announced the launch of the Noom Microdose GLP-1Rx Program, a groundbreaking offering designed to unlock weight loss and long-term health benefits while minimizing side effects through personalized microdoses of GLP-1 medication, when clinically appropriate
HFpEF appears to be the most common type of HF, representing around 50% of the cases, with HFmrEF accounting for 10%25% (Savarese et al., 2022)
Increased Energy & Vitality With improved mitochondrial function and better tissue repair, many patients report elevated energy levels , greater stamina , and a general sense of vitality
We suggest prospects and future directions for research on additional other nAChR and its mechanisms for treating ASD
Prevalence, classification, and severity of epilepsy and epileptic syndromes in children